Continuous Glucose Monitor (Freestyle Libre) prior authorization
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
This guideline defines prior authorization requirements for Freestyle Libre continuous glucose monitoring (CGM) products for members with diabetes and specifies initial and reauthorization criteria and documentation for CareOregon.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Authorization Criteria
Covered when ALL of the following are met for initial authorization (Type 2 and related diagnoses):
Examples of short-acting or intermediate-acting insulins listed in document (e.g., insulin aspart, insulin glulisine, insulin lispro, human regular insulins, NPH).
Order and options presented as alternates in source; any one satisfies this node.
Reauthorization Criteria
Reauthorization is approved when EITHER of the following is met:
Medical record documentation required.
Both conditions required for this option.
This prior authorization guideline applies to Freestyle Libre continuous glucose monitor (CGM) products. Coverage for initial authorization of Freestyle Libre is conditioned on meeting all specified criteria: the member must have an eligible diagnosis (for example, Type 2 diabetes mellitus, gestational diabetes, or diabetes due to an underlying condition), be currently using short-acting or intermediate-acting insulin, and meet at least one additional clinical criterion such as Hemoglobin A1c >= 8%, use of an insulin pump, a history of significant hypoglycemia (including nocturnal hypoglycemia or hypoglycemia unawareness), or evidence of diabetes-related complications. Specific approval lengths vary by diagnosis and therapy stage.
The source document does not include explicit not medically necessary statements for Freestyle Libre CGM devices. Coverage determinations are driven by the prior authorization criteria and required documentation outlined in this guideline; absence of a listing here should not be interpreted as clinical guidance beyond those criteria.
Coding & Clinical Thresholds
Provider Actions & Authorization
Prior authorization required for Freestyle Libre
Prior authorization is required for Freestyle Libre products. Initial authorization criteria apply for patients with Type 2 diabetes mellitus, gestational diabetes (or currently pregnant with type 2 diabetes), or diabetes due to underlying conditions (including drug- or chemical-induced diabetes).
- Product Name: Freestyle Libre Products (prior authorization guideline applies)
- Covered diagnoses for initial authorization: Type 2 diabetes mellitus; gestational diabetes (or pregnant with type 2 diabetes); diabetes due to underlying conditions
Therapy stage: initial vs reauthorization
Distinguish initial authorization (therapy stage: Initial Authorization for Type 2; approval lengths vary) from reauthorization (therapy stage: Reauthorization). The policy lists initial vs reauthorization stages but does not add further step-edit sequencing beyond these stages.
- Initial Authorization indicated for Type 2 diabetes (approval length shown)
- Reauthorization criteria and approval length are specified separately
Documentation required for reauthorization
For reauthorization, submit medical records or chart notes demonstrating either a significant improvement in GMI or A1c (10% reduction) since starting the CGM, OR documentation that the patient continues on short- or intermediate-acting insulin plus records confirming CGM use at least 50% of the time.
- Option 1: Medical records confirming a 10% reduction in GMI or A1c since CGM initiation
- Option 2: Documentation that patient continues short- or intermediate-acting insulin AND records showing CGM usage ≥ 50% of the time
Denial risk for missing insulin use or qualifying criteria
Denial risk if the chart does not document current use of short-acting or intermediate-acting insulin when required, or if the member fails to meet qualifying clinical criteria (e.g., hemoglobin A1c ≥ 8% or documented history of frequent/severe hypoglycemia).
- Insulin use required for initial authorization: patient must be currently on short-acting or intermediate-acting insulin
- Qualifying clinical criteria include A1c ≥ 8%, insulin pump use, history of frequent/severe hypoglycemia, or diabetes-related complications
Definitions
Background
Continuous glucose monitors provide near-real-time interstitial glucose measurements to support glycemic management for people using insulin. This guideline focuses on Freestyle Libre products and aligns coverage with insulin use and demonstrable clinical need: initial authorization requires current use of short-acting or intermediate-acting insulin plus at least one qualifying clinical indicator, while reauthorization may be granted when there is documentation of either a 10% reduction in GMI or A1c since starting CGM or evidence that the member is using the CGM at least >= 50% of the time and remains on short- or intermediate-acting insulin. Providers should submit relevant medical records (chart notes, A1c/GMI measurements, CGM usage data) to demonstrate these criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.